Cullinan Therapeutics Announces Results of 2026 Annual Meeting of Stockholders

On June 16, 2026, Cullinan Therapeutics, Inc. held its Annual Meeting of Stockholders. During the meeting, shareholders voted on three key proposals. First, stockholders elected Nadim Ahmed and Stephen Webster as Class III directors to the Board of Directors for three-year terms. Second, the appointment of KPMG LLP as the company\'s independent registered accounting firm for the fiscal year ending December 31, 2026, was ratified with an overwhelming majority of votes. Finally, stockholders approved an advisory vote on the compensation of the company\'s named executive officers ("say-on-pay"). The filing provides specific vote counts for each proposal, including votes for, withheld/against, abstentions, and broker non-votes. No other material corporate developments or clinical updates were disclosed in this filing.